Eli Lilly Aktie 947556 / US5324571083
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
30.10.2025 12:06:12
|
Eli Lilly Again Boosts FY25 Outlook - Update
(RTTNews) - While reporting financial results for the third quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2025, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.
For fiscal 2025, Eli Lilly now projects earnings in a range of $21.80 to $22.50 per share and adjusted earnings in a range of $23.00 to $23.70 per share on revenues between $63.0 billion and $63.5 billion.
Previously, the company expected earnings in the range of $20.85 to $22.10 per share and adjusted earnings in the range of $21.75 to $23.00 per share on revenues between $60.0 billion and $62.0 billion.
On average, analysts polled expect the company to report earnings of $22.50 per share on revenues of $61.63 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
